
    
      Participants with symptomatic TGCT will be administered pexidartinib 400 mg twice daily
      continuously with 28-day treatment cycle until criteria for discontinuation are reached.
      Participants who complete primary endpoint assessments may be eligible to continue receiving
      pexidartinib until disease progression, unacceptable toxicity, the occurrence of other
      termination criteria, or withdrawal from the study. Eligible participants' status will be
      collected every 6 months as a long term follow-up at least 2 years.
    
  